| Enasidenib studied in …STUDIED_INderived34 of 34show fewer |
|---|
| → studied in | NCT05564390Phase 2 · recruiting MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) · 34 trials list this drug (17 active) | — | — | Myelodysplastic Syndrome,Acute Myeloid Leukemia,Acute Myeloid Leukemia Arising from Previous Myelodysplastic/Myeloproliferative Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03839771Phase 3 · active not recruiting A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy · 34 trials list this drug (17 active) | — | — | Acute Myeloid Leukemia,Myelodysplastic Syndrome/Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06672146Phase 2 · recruiting Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial) · 34 trials list this drug (17 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06176989Phase 2 · recruiting Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors · 34 trials list this drug (17 active) | — | — | Chondrosarcoma,Large Cell Neuroendocrine Carcinoma,Olfactory Neuroblastoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03683433Phase 2 · recruiting Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation · 34 trials list this drug (17 active) | — | — | Myelodysplastic Syndrome,Acute Myeloid Leukemia,Chronic Myelomonocytic Leukemia+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03383575Phase 2 · recruiting Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome · 34 trials list this drug (17 active) | — | — | Acute Myeloid Leukemia,Chronic Myelomonocytic Leukemia,Myelodysplastic Syndrome with Excess Blasts | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03728335Phase 2 · suspended Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation · 34 trials list this drug (17 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06756308Phase 2 · active not recruiting A Study of Enasidenib in People With T-Cell Lymphoma · 34 trials list this drug (17 active) | — | — | T-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03744390Phase 2 · active not recruiting IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome · 34 trials list this drug (17 active) | — | — | Myelodysplastic Syndrome | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05010772Phase 1 · recruiting Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission · 34 trials list this drug (17 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02813135Phase 1/Phase 2 · recruiting European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors · 34 trials list this drug (17 active) | — | — | Childhood Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05401097Phase 2 · recruiting IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study) · 34 trials list this drug (17 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05756777Phase 1 · recruiting A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML) · 34 trials list this drug (17 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02632708Phase 1 · active not recruiting Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation · 34 trials list this drug (17 active) | — | — | Myelodysplastic Syndrome,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04774393Phase 1/Phase 2 · recruiting Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia · 34 trials list this drug (17 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05441514Phase 1 · completed Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia · 34 trials list this drug (17 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02677922Phase 1/Phase 2 · active not recruiting A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy · 34 trials list this drug (17 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05102370Phase 1 · completed A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance · 34 trials list this drug (17 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04203316Phase 2 · active not recruiting Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation · 34 trials list this drug (17 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03515512Phase 1 · completed IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation · 34 trials list this drug (17 active) | — | — | Acute Myeloid Leukemia,Chronic Myelomonocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02577406Phase 3 · completed An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation · 34 trials list this drug (17 active) | — | — | Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04281498Phase 2 · completed Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation · 34 trials list this drug (17 active) | — | — | Primary Myelofibrosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01915498Phase 1/Phase 2 · completed Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation · 34 trials list this drug (17 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04522895Phase 2 · completed IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT · 34 trials list this drug (17 active) | — | — | Leukemia,Myelodysplastic Syndrome,Chronic Myelomonocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04955938Phase 1 · withdrawn A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms · 34 trials list this drug (17 active) | — | — | Liquid Tumor,Myeloproliferative Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03878524Phase 1 · terminated Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial · 34 trials list this drug (17 active) | — | — | Hematopoietic and Lymphatic System Neoplasm,Hematopoietic and Lymphoid Cell Neoplasm,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03720366Phase 1 · completed A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients · 34 trials list this drug (17 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04092179Phase 1/Phase 2 · terminated Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers · 34 trials list this drug (17 active) | — | — | Malignant Neoplasm,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04075747Phase 1 · completed A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia · 34 trials list this drug (17 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03825796Phase 2 · active not recruiting CPX-351 Plus Enasidenib for Relapsed AML · 34 trials list this drug (17 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04655391Phase 1 · withdrawn Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation · 34 trials list this drug (17 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03881735Phase 2 · withdrawn Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation · 34 trials list this drug (17 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02273739Phase 1/Phase 2 · completed Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation · 34 trials list this drug (17 active) | — | — | Solid Neoplasm,Chondrosarcoma,Glioma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03723057no longer available Expanded Access for AG-221 · 34 trials list this drug (17 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |